AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells.

Journal of Cellular Biochemistry
Zhirui ZhangWu Yin

Abstract

AZD9291, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is highly selective against EGFR T790M-mutant non-small cell lung cancer (NSCLC). On investigating the growth inhibitory effects of AZD9291 on NSCLC and the underlying mechanism, we found that AZD9291 can trigger autophagy-mediated cell death in both A549 and H1975 cells by increasing the expression of phosphatidylethanolamine-modified microtubule-associated protein light-chain 3 (LC3) and decreasing the expression of p62. In the presence of the autophagy inhibitor chloroquine, the AZD9291-induced increase in LC3 level was further augmented. AZD9291 decreased the levels of phosphoinositide-3 kinase (PI3K), protein kinase B (Akt), and phosphorylated Akt. AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. AZD9291 was also found to significantly suppress the tumor growth in H1975 xenograft nude mice. Thus, AZD9291 was found to induce autophagy, decrease in EGFR levels, and show a strong inhibitory effect on NSCLC both in vitro and in vivo. Furthermore, the PI3K/Akt signaling pathway was found to play a critical role in AZD9291-induced cell death.

References

Mar 3, 2005·Journal of the National Cancer Institute·Hisayuki ShigematsuAdi F Gazdar
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lecia V Sequist, Rafal Dziadziuszko
May 3, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Federico CappuzzoMarileila Varella-Garcia
Nov 30, 2007·Cell·Yosef Yarden, Ben-Zion Shilo
May 1, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Olga C J SchuurbiersJohan Bussink
Oct 19, 2011·Environmental Microbiology·Margret E Berg MillerBryan A White
Mar 15, 2012·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Hee YiHo-Chul Shin
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kadoaki OhashiWilliam Pao
Jun 19, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yuan-Yuan LiJames Chung-Man Ho
Jan 7, 2014·Frontiers in Bioscience (Landmark Edition)·Paola Claudia SaccoCesare Gridelli
Mar 22, 2014·Molecular and Clinical Oncology·Xinbing SuiHongming Pan
May 31, 2014·Experimental Cell Research·Cheng-Yi ChangChun-Jung Chen
Oct 14, 2014·Frontiers in Oncology·Barbara Melosky
Apr 30, 2015·The New England Journal of Medicine·Pasi A JänneMalcolm Ranson
Jun 10, 2015·Journal of Bioenergetics and Biomembranes·Yiming SunHao Liu
Jan 6, 2016·Drugs·Sarah L Greig
Feb 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Don S DizonGregory Masters
Apr 14, 2016·Journal of Hematology & Oncology·Shuhang WangDelong Liu
Jun 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Melissa BersanelliMarcello Tiseo
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Peter BallardDarren Cross
Sep 24, 2016·Journal of Experimental & Clinical Cancer Research : CR·Zhirui ZhangHao Liu
Nov 26, 2016·Expert Review of Clinical Pharmacology·Kenzo SoejimaToshiyuki Hirano
May 24, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chien-Wei ChenChien-Chung Lin
May 27, 2017·Journal of Bioenergetics and Biomembranes·Zixuan ZhangHao Liu
Dec 5, 2017·Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer·Venugopal Vinod Prabhu, Niranjali Devaraj

❮ Previous
Next ❯

Citations

May 17, 2019·Cancer Biology & Therapy·Ruishuang MaHulun Li
Apr 8, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Bin XuLi Xu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Autophagy & Metabolism

Autophagy preserves the health of cells and tissues by replacing outdated and damaged cellular components with fresh ones. In starvation, it provides an internal source of nutrients for energy generation and, thus, survival. A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases. It does have a downside, however--cancer cells exploit it to survive in nutrient-poor tumors.

Autophagy & Model Organisms

Autophagy is a cellular process that allows degradation by the lysosome of cytoplasmic components such as proteins or organelles. Here is the latest research on autophagy & model organisms

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Autophagy Networks

Autophagy is a lysosomal pathway that involves degradation of proteins and functions in normal growth and pathological conditions, through a series of complex networks. The catabolic process involves delivery of proteins and organelles to the lysosome. Here is the latest research on autophagy networks.